Search

Your search for "mcurf" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference

January 6, 2022

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be participating in the H.C. Wainwright Bioconnect Conference; the multiday conference is scheduled for Jan. 10–13, 2022. According to the announcement, MINDCURE president and CEO Kelsey Ramsden will provide a virtual presentation, which will be available […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Inches Closer to iSTRYM’s Commercial Deployment; Announces Dr. Doron Sagman’s Appointment as CMO; and Avails Recent Life Sciences Virtual Conference Presentation for On-Demand Viewing

December 30, 2021

MINDCURE just announced receiving its HIPAA certification for iSTRYM, its AI-powered, SaaS platform for psychedelic therapy This marks a key milestone for the company, having already exceeded its target of 10 partner clinics by the end of 2021 It also inches the company closer to the platform’s commercial deployment, set for the second quarter of […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Recognized as One of the Best Women-Led Workplaces, Participates in the December 16 Life Sciences Virtual Investor Conference

December 27, 2021

The Great Place to Work organization included MINDCURE in its 2021 list of the Best Workplaces Managed by Women The company was recognized for its employee-oriented perks and programs, which include flexible working hours, monthly team-building events, and a remote work office stipend MINDCURE also participated in the Life Sciences Virtual Investor Conference held on […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Advancing Core Research, Commercial Production Programs, Identifying Pipeline Expansion Opportunities

December 20, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently provided an update sharing significant milestones reached in 2021 for both of its operating arms, MINDCURE Research and MINDCURE Technology. MINDCURE Research offered several updates, including important milestones in its synthetic ibogaine manufacturing; the company is […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Significant Milestone That Brings iSTRYM Closer to Commercial Deployment

December 16, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced that the company and its digital therapeutics technology, iSTRYM, have been certified as Health Insurance Portability and Accountability Act (“HIPAA”) compliant. HIPAA compliance certification reflects MINDCURE’s commitment to achieving the highest standards of […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Strategic CMO Appointment of Dr. Doron Sagman

December 14, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced its appointment of Doron Sagman, MD, FRCPC, as the company’s new chief medical officer (“CMO”). Per the update, Dr. Joel Raskin, who was acting CMO, will transition into an advisory role for MINDCURE. […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Discusses Psychedelics Research, Life Sciences Focus, at Key Industry Conferences

December 10, 2021

MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research Company reports that 971 million […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Delivering Evidence-Based DTx, Research Centered Around Psychedelics

December 8, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently released an operational update regarding the strategic initiatives of its operating segments – MINDCURE Research and MINDCURE Technology. The update detailed the company’s progress and plans for the immediate future. “As a member of the Digital […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in December 2021 Conferences

December 3, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be featured in several upcoming conferences. The company announced that president and CEO Kelsey Ramsden has been invited to present in four virtual conferences scheduled in December. Those conferences include the H.C. Wainwright’s second annual […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Research and Technology Progress, Offers Corporate Update

Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platform MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide In July, MINDCURE filed for patents on […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Divisional Update Highlights Consistent Program and Product Progress Across the Board

November 30, 2021

MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022 The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022 Information on MC-106 and MC-808, an expansion of […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Featured in Equity Research Report

November 15, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, was featured in a recent equity research report. The coverage, initiated by Maxim Group LLC, highlights MINDCURE’s efforts to set the stage to unlock value for the company. This includes work on its ongoing programs […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion

November 12, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently signed a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing and delivering psychedelic medicine to treat addiction. “Under the LOI, MINDCURE […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

November 4, 2021

The distribution component unlocks a new revenue source for the company, helping drive future growth MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Provides Studies, Clinical Trials Update

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has released an update on strategic initiatives related to its MINDCURE Research and MINDCURE Technology divisions. According to the company, its synthetic ibogaine efforts, which were announced in March 2021, include the application for two patents […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol

October 28, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has signed a nonbinding letter of intent with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF). Awakn is a biotechnology company with clinical operations focused on researching, developing and delivering psychedelic medicine to better treat addiction. According to […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Sponsor, Participate In Upcoming Events

October 27, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, announced its participation in two upcoming November events. The company will be a silver sponsor of Wonderland Miami, the largest in-person conference focused on the psychedelic medicine industry. At Wonderland, MINDCURE president and CEO Kelsey Ramsden will participate […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Identifies Market Gap, Launches ‘Desire Project’

October 22, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently launched its “Desire Project” to address and treat female hypoactive sexual desire disorder (“HSDD”) with MDMA-assisted psychotherapy. A first-of-its-kind study, the Desire Project, is targeting HSDD, a common sexual disorder characterized by a persistent, low sexual drive […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Focusing on What It Does Best

October 15, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently released its financial results for the twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. “The company initially began the year developing a nootropic line of functional mushrooms […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) to Present at KCSA Psychedelics Virtual Investor Conference

October 7, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced that its president and CEO Kelsey Ramsden will present virtually at the KCSA Psychedelics Investor Conference, which will be held Oct. 13-14, 2021, at VirtualInvestorConferences.com. Ramsden’s presentation is scheduled to begin at 12 […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021

October 4, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Launches The Desire Project to Promote MDMA-Assisted Psychotherapy Treatment for HSDD

October 1, 2021

Although an often unspoken of medical disorder, Hypoactive Sexual Desire Disorder affects approximately 9.5 million women in the U.S. alone The project gathers some of the world’s leading researchers in female sexual desire and psychedelics This is the first-of-its-kind psychedelic-based treatment program targeting this disorder, with potential global implications Clinical trials of MDMA as a […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Commences Trading on the OTCQX Best Market

September 30, 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that it has graduated from the OTCQB Venture Market to now trade on the OTCQX Best Market, the highest tier of OTC Markets Group. “Receiving approval to trade on the OTCQX is an […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Present at Benzinga Healthcare Small Cap Conference

September 28, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that its CEO and President Kelsey Ramsden will present and participate in one-on-one investor meetings at the Benzinga Healthcare Small Cap Conference. The event is scheduled to be held virtually on Sept. 29-30, […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Launch of the ‘Desire Project’

September 27, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today unveiled its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. According to the update, the research program will mark the first psychedelic-based treatment […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to be Included in AdvisorShares Psychedelics ETF

September 22, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has been included in the new AdvisorShares Psychedelics ETF. The ETF will be traded on the NYSE Arca using the PSIL ticker symbol. The PSIL symbol includes biotechnology, pharmaceutical and life sciences companies that have been […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference

September 17, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that president and CEO Kelsey Ramsden will be participating in the Advances in Mental Health Virtual Conference. The one-day conference, presented by Maxim Group LLC and hosted by M-Vest, is scheduled for Sept. 22, […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

September 16, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, is joining the Digital Therapeutics Alliance. A nonprofit association of industry leaders, the alliance is dedicated to driving awareness and adoption of digital therapies. MINDCURE announced that, as part of the alliance, the company is committed […]

News Articles

Potential for Psychedelic treatments Drives Mind Cure Health Inc.’s (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Strategy for Therapeutics Profitability

September 15, 2021

Canada-based life sciences company Mind Cure Health is developing a synthetic form of the psychedelic drug ibogaine as part of its efforts to take a leading position in the burgeoning market for mental health therapies Psychedelics, strengthened by new clinical research driving scientific and legislative openness to the drugs’ possible benefits under controlled conditions, are […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is Frontrunner in Support of Psychedelic-Assisted Therapy

September 14, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, is devoted to building access to safe, science- and evidence-backed psychedelic-assisted therapies globally. “The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview

September 10, 2021

Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug development On the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Share Company’s Mission, iSTRYM Developments at 2021 SANA Symposium

September 9, 2021

MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced its presence at the 2021 SANA Symposium as a platinum sponsor and host of the Innovation Theater. According to the update, MINDCURE will be engaging with clinicians around the world interested in learning more about psychedelic-assisted psychotherapy, […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) to Participate in H.C. Wainwright Global Investment Conference

September 8, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that it will featured at the upcoming H.C. Wainwright 23rd annual Global Investment Conference. The three-day conference is scheduled to begin Sept. 13 and runs through Sept. 15, 2021. MINDCURE president and CEO Kelsey Ramsden will present […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Leveraging Strategic Board Appointment to Execute Visionary Strategy

August 31, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently announced its appointment of Jerry White as an advisor to the company. White has been recognized for his efforts in engaging large audiences to power global movements and is a recognized leader of the International Campaign to […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Releases First-of-Its-Kind Digital Therapeutics Platform to Partner Clinics in North America

August 26, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, today announced the release of the minimum viable product version of iSTRYM, its digital therapeutics platform (“DTx”) for psychedelics, into partner clinics across North America. According to the update, the company will begin full commercial deployment […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

August 20, 2021

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine  In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing  This year has also seen the launch of the second […]

InvestorNewsBreaks

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Co-Founder, CEO Featured on Bell2Bell Podcast

August 19, 2021

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Welcomes Digital Technology Expert in Development of Doctor-Patient SaaS Tech

August 17, 2021

Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology  The company is focused on developing digital therapeutics technology and researching psychedelic compounds The company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists  On the research side, […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Featured in Coverage of Investor Summit Group’s Q3 Virtual Event

August 13, 2021

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. For more information, visit the company’s […]

News Articles

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Bolsters its Advisory Board With The Appointment of Jerry White

Mind Cure Health Inc. announced Jerry White’s appointment into the company’s advisory board Mr. White brings a wealth of experience from his years of powering global movements and working with key leaders and personalities around the world MINDCURE forecasts that with Mr. White’s addition to the board, the company will be well-positioned to achieve bigger […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).